Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 30 November 2023

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the manufacturing, supply, and importation of therapeutic goods in Australia. This Act was introduced to address the need for a comprehensive legal framework that ensures the quality, safety, and efficacy of therapeutic goods available to the public. The Therapeutic Goods Administration (TGA), a division of the Department of Health and Aged Care, is the primary body responsible for administering and enforcing the provisions of this Act. The policy objective of the Act is to protect public health by ensuring that therapeutic goods are of acceptable quality and are used safely. It achieves this by requiring manufacturers and suppliers to hold appropriate licences and by regulating the manufacture, supply, and importation processes to maintain high standards. The Gazetted publication of the list of manufacturers granted a licence for the manufacture of therapeutic goods, as seen in the 30 November 2023 notice, is a practical implementation of the Therapeutic Goods Act 1989. This notice, issued by Katherine Clark, Delegate of the Secretary of the Department of Health and Aged Care, provides public acknowledgment of the licence granted to specific companies, ensuring transparency and accountability in the therapeutic goods industry. By doing so, it upholds the Act’s goal of safeguarding the health and well-being of Australians through stringent regulatory measures.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities that are involved in the manufacture, supply, or distribution of therapeutic goods within Australia. The Act regulates these goods to ensure they are of acceptable quality, efficacy, and safety for consumers. It applies to various industries, including pharmaceuticals, medical devices, and cosmetics. The Act governs the conduct and transactions related to therapeutic goods, ensuring compliance with standards set by the Therapeutic Goods Administration (TGA). The jurisdictional reach of the Act is national, applying across all states and territories of Australia, as it is a Commonwealth Act. The Act includes provisions for granting licences to manufacturers, as seen in the recent publication regarding Slade Health Pty Ltd, Medcan Australia Pty Ltd, and Pharmsky Research (Australia) Pty Ltd, each granted specific licences to manufacture therapeutic goods. The Act does not specify exclusions or exemptions but allows for certain exclusions through subordinate instruments, such as regulations that may further detail the types of therapeutic goods and the specific requirements for their manufacture and distribution.

Key Provisions

Section 38 of the Therapeutic Goods Act 1989 (the Act) facilitates the issuance of licences to entities for the manufacture of therapeutic goods. The Act requires that only entities that meet the necessary quality and safety standards may manufacture these goods. Specifically, Section 38 permits the Secretary to grant a licence to an entity after assessing its manufacturing facilities and practices to ensure compliance with the Act's requirements. The licence details, including the manufacturer's name and address, are published under this section to ensure transparency and accountability. This year, the Therapeutic Goods Administration has granted licences to Slade Health Pty Ltd, Medcan Australia Pty Ltd ATF Medcan Australia Trust, and Pharmsky Research (Australia) Pty Ltd, as evidenced by their respective licence numbers and addresses. Entities granted a licence under Section 38 are subject to stringent obligations and requirements. They must adhere to the manufacturing standards and practices outlined in the Act to ensure the quality and safety of the therapeutic goods they produce. This includes maintaining proper documentation, conducting regular inspections, and reporting any adverse events associated with their products. The licensed entities are also required to comply with any additional conditions specified in their licence, which may include periodic audits by the Therapeutic Goods Administration to verify ongoing compliance. Failure to meet these obligations can result in the suspension or revocation of the licence. The Therapeutic Goods Act 1989 imposes serious consequences for breaches of its provisions. Section 42A outlines the offences related to the unauthorised manufacture of therapeutic goods, with penalties that include substantial fines and imprisonment. Specifically, an individual can be fined up to $220,000 and/or imprisoned for up to five years, while a body corporate can be fined up to $1,100,000. Additionally, Section 42B addresses offences related to the sale of unauthorised therapeutic goods, with penalties that include fines of up to $550,000 for individuals and $2,750,000 for bodies corporate, alongside potential imprisonment terms. These severe penalties underscore the importance of compliance with the Act's requirements to protect public health and safety.